SCHEMBL13906785

SCHEMBL13906785

CC(=O)OC[C@H]1O[C@@H](n2cc3c4c(ncnc42)NC(=O)C=C3N)C(C)(O)[C@@H]1OC(C)=O

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ THRB P10828 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.31
▸ ADK P55263 1/20 0.31
▸ PRKAB2 O43741 1/20 0.30
▸ PRKAG1 P54619 1/20 0.30
▸ PRKAA2 P54646 1/20 0.30
▸ PRKAA1 Q13131 1/20 0.30
▸ PRKAG3 Q9UGI9 1/20 0.30
▸ PRKAG2 Q9UGJ0 1/20 0.30
▸ PRKAB1 Q9Y478 1/20 0.30
▸ PTPN1 P18031 1/20 0.30
▸ ADORA3 P0DMS8 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3952292 1.00 ADORA2A (0.33) ADORA2ALMNATHRBSMN1; SMN2HIF1A
SCHEMBL3957754 0.92 ADORA2A (0.39) ADORA2AHIF1AALDH1A1ADKADORA3
SCHEMBL13906745 0.92 ADORA2A (0.39) ADORA2AHIF1AALDH1A1ADKADORA3
SCHEMBL4135629 0.91 ADORA2A (0.40) ADORA2AADORA3
SCHEMBL13904935 0.91 ADORA2A (0.40) ADORA2AADORA3
SCHEMBL13906749 0.91 LMNA (0.32) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL3948809 0.91 LMNA (0.32) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL4020116 0.91 LMNA (0.32) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL3952015 0.90 ADORA2A (0.31) ADORA2A
SCHEMBL13906783 0.89 ADORA2A (0.32) ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062223-A1 AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-03-05 — — US disclosed
US-20090062223-A1 AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062223-A1 AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE PNP, SLC29A1, SLC28A1 ADORA2A 277/4885LMNA 710/4885THRB 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback